This article is based on the research, MSH3 Homology and Potential Recombination Link to SARS-CoV-2 Furin Cleavage Site published in the peer-reviewed journal Frontiers in Virology. Briefly, it talks about the genetic sequence present in the SARS-CoV-2 virus that caused the COVID-19 pandemic to be similar to a nucleotide sequence patented by Moderna in 2016. [1]
What is the patent number?
A BLAST search for the 12-nucleotide insertion led us to a 100% reverse match in a proprietary sequence (SEQ ID11652, nt 2751-2733) found in the US patent 9,587,003. It is filed on Feb. 4, 2016 [2]
How did they find the similarities?
By using the Basic Local Alignment Search Tool (BLAST). On its NCBI page,
BLAST finds regions of local similarity between sequences. The program compares nucleotide or protein sequences to sequence databases and calculates the statistical significance of matches.
What is the chance that the similarity is a coincidence?
Conventional biostatistical analysis indicates that the probability of this sequence randomly being present in a 30,000-nucleotide viral genome is 3.21 ×10−11
What part of the SARS-CoV-2 is similar to the Moderna sequence?
A BLAST search revealed that a 19 nucleotide portion of the SARS-Cov-2 genome encompassing the furin cleavage site is a 100% complementary match to a codon-optimized proprietary sequence that is the reverse complement of the human mutS homolog (MSH3).
The figure below shows PRRA amino acid sequence in the Furin cleavage site. PRRA are the letter codes for Proline, ARginine, ARginine, Alanine. CCT CGG, CGG, and GCA are the codons that code for amino acids.
CCT CGG CGG, and GCA are also found in Seq 1D11652 from the US patent 9587003 that is filed by Moderna[2]
Why did Moderna patent that sequence?
One cause of cancer is a defect in DNA repair called mismatch repair deficiency. The proprietary sequence SEQ ID11652 is likely for cancer treatment.
The proprietary sequence SEQ ID11652, read in the forward direction, encodes a 100% amino acid match to the human mut S homolog 3 (MSH3). MSH3 is a DNA mismatch repair protein (part of the MutS beta complex).
MSH3 replacement with a codon-optimized mRNA sequence for human expression likely has applications in cancers with mismatch repair deficiencies.
Is that patented sequence present in other coronaviruses?
The presence of two consecutive CGG codons is rare in coronaviruses. The Relative Synonymous Codon Usage (RSCU) measures codon frequency.
Here are the RSCU of CGG in the following coronaviruses [3]
- Pangolin coronavirus – 0
- Bat coronavirus – 0.08
- SARS Coronavirus – 0.19
- MERS Coronavirus – 0.25
- SARS-CoV-2 – 0.299.
Is it possible that the SARS-CoV-2 virus obtained that sequence from an intermediate host like another animal?
The absence of CTCCTCGGCGGGCACGTAG from any eukaryotic or viral genome in the BLAST database makes recombination in an intermediate host an unlikely explanation for its presence in SARS-CoV-2.
Where can you find the patented sequence in the SARS-CoV-2, and how did it affect its function?
The image above shows that the sequence similar to the Moderna patent can be found in the furin cleavage site. It increases the affinity of the SARS-CoV-2 to the ACE2 receptor and makes it more infectious than the other coronaviruses including the MERS and SARS viruses.
Maria Bartiromo interviewed the CEO of Moderna Stephane Bancel about the issue at 7:35. He said that Moderna’s scientists are looking into it.
You can see the name of the CEO on the patent below[2].
Yes, I’m sure that the similarity in the nucleotide sequence between the pandemic virus and the maker of the jab that made them 7.2 billion in 2021 is all a coincidence. (sarcasm)
Truth heals. Lies kill. Don’t Get Sick!
Knowledge about Covid-19 is rapidly evolving. Stay current by subscribing. Feel free to share and like.
If you find value in this website, please consider donating to show your support.
Related:
- Moderna’s study shows the ineffectiveness of their shots against the Omicron and why they recommend a booster
- SARS-CoV-2 spike proteins detected in the plasma following Moderna shots
- The Pfizer and Moderna booster shots are about 50% effective
- The Durability Study of the Moderna COVID-19 Vaccine is Strange and Unusual
- Lot Numbers of Pfizer and Moderna mRNA Vaccines with the Highest Deaths
- This 42-day study prompted FDA to approve Moderna booster shots for immune-compromised
- Myocarditis after mRNA Vaccination in the Military
- Study: Most antibodies produced by mRNA vaccines are Non-neutralizing
- Doctor reveals how to minimize mRNA vaccine side effects
References:
- Ambati et al. MSH3 Homology and Potential Recombination Link to SARS-CoV-2 Furin Cleavage Site. Front.Virol., 21 February 2022.
- Bancel S, Chakraborty T, De Fougerolles A, Elbashir SM, John M, Roy A, et al. Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides. Cambridge, MA: United States Patent. (2016).
- Kandeel M, Ibrahim A, Fayez M, Al-Nazawi M. From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. J Med Virol. (2020) 92:660–6. doi: 10.1002/JVM.25754© 2018 – 2022 Asclepiades Medicine, L.L.C. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatmentAs an Amazon Associate, I earn from qualifying purchases.